Much of preclinical research into one cancer drug is flawed, says report
A review of preclinical research of a now widely used cancer drug suggests the studies contain multiple methodology flaws and overestimate the benefits of the drug. Specifically, the researchers found that most studies didn’t randomize treatments, didn’t blind investigators to which animals were receiving the drug, and tested tumors in only one animal model, which limits the … Continue reading Much of preclinical research into one cancer drug is flawed, says report